Skip to main content
S&P 5007,712.57+0.28%DOW52,495.88+1.02%NASDAQ26,424.82-0.02%BTC$83,097.00+1.89%ETH$2,455.36+2.50%GOLD$4,138.20-0.11%OIL$98.47+0.66%
Smart Investors Daily
SID Premium
ML

NASDAQ · MLYS

Mineralys Therapeutics, Inc.

Healthcare · Biotechnology

$20.92

Up+$0.66 (+3.15%)

Updated Oct 21, 2026, 12:21 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.39B
P/E ratio
-12.37
Dividend yield
0.00%
52-week range
$20.12 – $47.65
Volume
1.12M
Avg. volume
1.48M

Price performance · MLYS

MLYS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 19, 2026

MLYS closed at $20.92 after 20 trading sessions, down 28.84% for the selected period.

Last close
$20.92
Period change
-28.84%
Period low
$20.30
Period high
$29.40
Daily close
View OHLC price history
MLYS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 19, 2026$20.57$21.11$20.27$20.921.12M
Oct 16, 2026$21.60$21.60$20.12$20.301.18M
Oct 15, 2026$21.04$21.83$20.825$21.641.09M
Oct 14, 2026$20.74$22.2337$20.61$20.761.16M
Oct 13, 2026$22.04$22.815$20.41$21.003.35M
Oct 12, 2026$22.90$23.10$22.165$22.231M
Oct 9, 2026$22.49$23.68$22.365$23.37895.31K
Oct 8, 2026$22.245$22.39$21.46$22.382.25M
Oct 7, 2026$21.78$22.44$21.485$22.09989.12K
Oct 6, 2026$23.54$23.54$21.88$21.951.22M
Oct 5, 2026$23.98$23.9999$22.97$23.301.08M
Oct 2, 2026$24.01$24.34$23.55$23.63928.3K
Oct 1, 2026$25.13$25.34$23.58$23.721.65M
Sep 30, 2026$24.48$25.8899$24.44$25.132.05M
Sep 29, 2026$25.39$25.78$24.43$24.481.72M
Sep 28, 2026$25.46$25.95$24.92$25.631.7M
Sep 25, 2026$26.55$26.70$25.21$25.861.19M
Sep 24, 2026$26.77$27.07$25.83$26.59895.4K
Sep 23, 2026$29.36$29.83$26.62$26.891.48M
Sep 22, 2026$28.63$29.55$28.37$29.40849.46K

Latest MLYS news

The latest Smart Investors Daily articles mentioning MLYS.

Stock researchCompany · Overview

MLYS research

Overview

Company profile and research snapshot.

Company profile

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$52.00
Implied upside
—
Analysts
—
MLYS recent ratings
DateFirmRatingTarget
Oct 12, 2026UBSNeutral—
Oct 12, 2026HC Wainwright & Co.Buy—
Apr 27, 2026TD CowenBuy—
Mar 13, 2026B of A SecuritiesBuy—
Dec 19, 2025StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats

The addition of Ms. Peterson and Mr. Coats brings additional commercial and product launch experience to Mineralys ahead of the December 22 PDUFA target action date for lorundrostatRADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases drive

Yahoo · Oct 12, 2026

Mineralys Therapeutics (MLYS) Shares New Lorundrostat Data, Is The Stock A Bargain?

New lorundrostat data puts Mineralys Therapeutics in focus Mineralys Therapeutics (MLYS) has drawn fresh attention after sharing new analyses from its Phase 3 Launch-HTN and Phase 2 Explore-OSA trials, highlighting lorundrostat's performance in uncontrolled hypertension and sleep apnea. The company reported that 46% of lorundrostat treated participants in Launch-HTN reached the AHA/ACC recommended office systolic blood pressure target at Week 12. This is a key clinical outcome for patients...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By